Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

NRX Pharmaceuticals (NRXP) Accumulated Depreciation & Amortization (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Accumulated Depreciation & Amortization for 2 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 57.89% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30000.0 through Dec 2025, up 57.89% year-over-year, with the annual reading at $30000.0 for FY2025, 57.89% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $30000.0 at NRX Pharmaceuticals, up from $24000.0 in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $30000.0 in Q4 2025, with the low at $19000.0 in Q4 2024.